Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study
Year: 2025
Type: article
Language: en
Topic: Bladder and Urothelial Cancer Treatments
Authors and affiliations:
raw_author_name: Xuanjun Guo
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Shuoyu Wang
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Yechi Ma
raw_affiliation_strings: Peking University Health Science Center, Beijing, China
raw_author_name: Yicong Du
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Yuke Chen
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Qian Wang
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Kaiwei Yang
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Qi Tang
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Yu Fan
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Han Hao
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Zhisong He
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Yanqing Gong
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. yqgong@bjmu.edu.cn
Department of Urology, Peking University First Hospital, Beijing, China. yqgong@bjmu.edu.cn
Institute of Urology, Peking University, Beijing, China. yqgong@bjmu.edu.cn
National Urological Cancer Center, Beijing, China. yqgong@bjmu.edu.cn
Urothelial Cancer Center, Peking University First Hospital, Beijing, China. yqgong@bjmu.edu.cn
Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China
Department of Urology, Peking University First Hospital, Beijing, China
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
raw_author_name: Cuijian Zhang
raw_affiliation_strings: Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China. surgeon_zhang@126.com
Department of Urology, Peking University First Hospital, Beijing, China. surgeon_zhang@126.com
Institute of Urology, Peking University, Beijing, China. surgeon_zhang@126.com
National Urological Cancer Center, Beijing, China. surgeon_zhang@126.com
Urothelial Cancer Center, Peking University First Hospital, Beijing, China. surgeon_zhang@126.com
National Urological Cancer Center, Beijing, China
Urothelial Cancer Center, Peking University First Hospital, Beijing, China
Institute of Urology, Peking University, Beijing, China
Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China